U.S. Adults With Diabetes Take Control of Care Through Innovative Use of Digital Resources

Manhattan ResearchMore than ever, type 1 and type 2 diabetes patients are turning to online channels to research treatment and product information, to seek advice and support from others, and to manage their condition. According to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Health™ study, nine out of ten online diabetes patients use the Internet to research health information, and two-thirds use the Internet to access pharmaceutical product information.

More so than other therapeutic categories, diabetes patients have an extremely active blog community. Celebrity diabetes patients have also gotten involved in the online mix - singer Nick Jonas teamed up with Bayer Healthcare to launch NickSimpleWins.com, a diabetes awareness site featuring a blog, online videos, and links to songs from The Jonas Brothers.

A few diabetes product websites have been particularly successful in serving the needs of consumers online over the past year. According to Manhattan Research's ePharma Consumer® study, Sanofi-Aventis' Lantus.com is the highest-rated site in terms of visitor satisfaction, out of a pool of more than 200 product websites. Consumers applaud the site's "very informative, interactive instruction guides" and appreciate that "all medical information is thoroughly disclosed." Consumers also rated Merck's Januvia.com as one of the top pharmaceutical product brand sites for visitor satisfaction.

Request a Complimentary Overview of Online Diabetes Market
Manhattan Research offers a complimentary overview of how diabetes patients use the Internet and other technology for healthcare. This one-page snapshot is a preview of the Diabetes Segmentation Module, which is a comprehensive analysis of the diabetes patient market based on Cybercitizen Health™ and ePharma Consumer®. To request your complimentary snapshot of the diabetes market or any of the other 100+ consumer therapeutic groups we cover, please visit www.manhattanresearch.com/products/Therapeutic_Segmentations/therapeutic-segmentation-overview-request.aspx

Consumer and Physician Segmentation Modules
Manhattan Research provides comprehensive analyses of over 125+ consumer therapeutic and physician specialist groups. Each Segmentation Module is an in-depth view of a particular market’s adoption and use of the Internet and other technology for healthcare, treatment, and product decisions and focuses heavily on tactical execution. The segmentation modules provide clients with the necessary market data and insights to make better informed decisions during brand planning and to connect with a particular disease class or specialist group through digital strategies.

Consumer therapeutic module topics include media consumption across traditional and alternative resource channels, website usage metrics, connectivity and interaction with physicians, health site engagement, use of branded and unbranded product sites, Web 2.0, interest in online health services and tools, DTC advertising, actions taken offline after health info seeking, and drivers to requesting a prescription drug.

Physician specialist module topics include interactive detailing, Web 2.0, pharmaceutical customer service portals, tech-enabled sales reps, search engines, online and offline professional information sources, email use and opportunity, patient interaction and education, digital health infrastructure, and mobile technology profile.

For a list of available consumer therapeutic segmentation modules and topics, please visit www.manhattanresearch.com/products/Therapeutic_Segmentations

For a list of available physician specialist segmentation modules and topics, please visit www.manhattanresearch.com/products/Specialist_Segmentations

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health™, Cybercitizen Health™ Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic segments and 25 physician specialist segments. For information, please visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...